Abstract:Abstract Background Understanding the synergetic and antagonistic effects of combinations of drugs and toxins is vital for many applications, including treatment of multifactorial diseases and ecotoxicological monitoring. Synergy is usually assessed by comparing the response of drug combinations to a predicted non-interactive response from reference (null) models. Possible choices of null models are Loewe additivity, Bliss independence and the recently rediscovered Hand model. A different approach is taken by the MuSyC model, which directly fits a generalization of the Hill model to the data. All of these models, however, fit the dose–response relationship with a parametric model. Results We propose the Hand-GP model, a non-parametric model based on the combination of the Hand model with Gaussian processes. We introduce a new logarithmic squared exponential kernel for the Gaussian process which captures the logarithmic dependence of response on dose. From the monotherapeutic response and the Hand principle, we construct a null reference response and synergy is assessed from the difference between this null reference and the Gaussian process fitted response. Statistical significance of the difference is assessed from the confidence intervals of the Gaussian process fits. We evaluate performance of our model on a simulated data set from Greco, two simulated data sets of our own design and two benchmark data sets from Chou and Talalay. We compare the Hand-GP model to standard synergy models and show that our model performs better on these data sets. We also compare our model to the MuSyC model as an example of a recent method on these five data sets and on two-drug combination screens: Mott et al. anti-malarial screen and O’Neil et al. anti-cancer screen. We identify cases in which the HandGP model is preferred and cases in which the MuSyC model is preferred. Conclusion The Hand-GP model is a flexible model to capture synergy. Its non-parametric and probabilistic nature allows it to model a wide variety of response patterns.

Current Methods for Quantifying Drug Synergism.

Synergy detection: A practical guide to statistical assessment of potential drug combinations

Advances in computational approaches in identifying synergistic drug combinations.

Statistical determination of synergy based on Bliss definition of drugs independence

Searching for Synergism Among Combinations of Drugs of Abuse and the Use of Isobolographic Analysis

Discovering Synergistic Drug Combination from a Computational Perspective

Evaluation of Drug Combination Effect Using a Bliss Independence Dose–Response Surface Model

Review of Predicting Synergistic Drug Combinations

What Does It Take to Synergistically Combine Sub-Potent Natural Products into Drug-Level Potent Combinations?

A Bayesian approach to study synergistic interaction effects in in-vitro drug combination experiments

Mechanisms of Drug Combinations: Interaction and Network Perspectives.

A Two-Stage Response Surface Approach to Modeling Drug Interaction

Synergy evaluation by a pathway-pathway interaction network: a new way to predict drug combination.

MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery

Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?

Abstract 943: Identification and validation of unusual drug combinations identified from combination databases

A review of machine learning approaches for drug synergy prediction in cancer

Non-parametric synergy modeling of chemical compounds with Gaussian processes

SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction

Comparison of methods for evaluating drug-drug interaction

Predicting and Quantifying Antagonistic Effects of Natural Compounds Given with Chemotherapeutic Agents: Applications for High-Throughput Screening